1. Weiden PJ, et al. Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study. American Journal of Psychiatry 1991; 286: 1229-1230.
2. Caldwell A. The history of psychopharmacology. In: Clark WG, del Giudice J, editors. Principles of Psychopharmacology (2nd Edn). New York: Academic Press, 1978: 9-40.
3. NIDS Working Group. Neuroleptic-Induced Deficit Syndrome (NIDS). Journal of Clinical Psychiatry 1993; 54: 493-500.
4. Hoge S, Appelbaum P, Lawlor T, et al. A prospective, multicenter study of patients’ refusal of antipsychotic medication. Archives of General Psychiatry 1990; 47(10): 949-956.
5. Kraepelin E. Dementia Praecox and Paraphrenia (translated by Barclay RM). Edinburgh: E & S Livingstone, 1919.
6. Owens D, Johnstone E. Spontaneous involuntary disorders of movement. Archives of General Psychiatry 1982; 39: 452-461.
7. Chorfi M, Moussaoui D. Les schizophrenes jamais traites n’ ont pas de movements anormaux type dyskinesia tardive. L’Encéphale 1985; 11: 263-265.
8. McCreadie R, Ohaeri J. Movement disorder in never and minimally treated Nigerian schizophrenic patients. British Journal of Psychiatry 1994; 164: 184-189.
9. McCreadie R, Thara R, Kamata S, et al. Abnormal movements in never medicated Indian patients with schizophrenia. British Journal of Psychiatry 1996; 168: 221-226.
10. Schooler N, Kane J. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486-487.
11. Gershanik O. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs and Aging 1994; 5(2): 127-132.
12. Beasley C, et al. Olanzapine versus placebo: results of a double-blind fixed dose trial. Psychopharmacology 1996; 124: 159-167.
13. Marder S, Meibach R. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994; 151: 825-835.
14. Casey D. Extrapyramidal syndromes: epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996; 5(1): 1-12.
15. Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophrenia Bulletin 1995; 21(3): 451-461.
16. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Archives of General Psychiatry 1994; 51(12): 963-974.
17. Fleischhacker C, Miller P, Schett C, et al. The Hillside Akathisia Scale: a reliability comparison of the English and German versions. Psychopharmacology 1991; 105: 141-144.
18. Fleischhacker WW, Miller C, Barnas C, et al. The effect of activation procedures on neuroleptic induced akathisia. British Journal of Psychiatry 1993; 163: 781-784.
19. Miller C, Hummer M, Oberbauer H, et al. Dose escalation influences the risk of neuroleptic induced akathisia. European Journal of Neuropsychopharmacology 1996; in press.
20. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic induced akathisia. Journal of Clinical Psychopharmacology 1990; 10: 12-21.
21. Miller C, Hummer M, Kurzthaler I, et al. A double blind treatment trial of ritanserin in neuroleptic induced akathisia. Journal of Clinical Psycopharmacology 1996; in press.
22. Miller C, Hummer M, Pycha R, et al. The effect of ritanserin on treatment resistant neuroleptic induced akathisia: case reports. Neuro-Psychopharmacology & Biological Psychiatry 1992; 16: 247-251.
23. Hummer M, Fleischhacker W. Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal syndromes. CNS Drugs 1996; 5(1): 13-20.
24. Barnes TRE. Movement disorder associated with antipsychotic drugs: the tardive syndromes. International Review of Psychiatry 1990; 2: 355-366.
25. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: A Taskforce report of the American Psychiatric Association. American Psychiatric Association; 1992.
26. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry 1995; 52: 756-765.
27. Klawans HI, Goetz CG, Perlik S. Tardive dyskinesia, review and update. American Journal of Psychiatry 1980; 137: 900-908.
28. Burke RE, Kang UJ, Jankovic J, et al. Tardive dyskinesia: and analysis of clinical features and response to open therapeutic trials. Movement Disorders 1989; 4: 157-175.
29. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Archives of General Psychiatry 1985; 42: 874-878.
30. Hennessy RE, Barnes TRE, Halstead SM. Follow-up study of chronic akathisia in a schizophrenic inpatient population (Abstract). Schizophrenia Research 1994; 11: 194.
31. Liddle PR, Barnes TRE, Speller JC, Kibel D. Negative symptoms as a risk factor for orofacial dyskinesia. British Journal of Psychiatry 1993; 163: 776-780.
32. Waddington JL. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants and the conflict of paradigms. International Review of Neurobiology 1989; 31: 297-353.
33. Pantelis C, Barnes TRE, Nelson HF. Is the concept of subcortical dementia relevant to schizophrenia? British Journal of Psychiatry 1992; 160: 442-460.
34. Kane JM, Werner M, Borenstein M. Tardive dyskinesia incidence and outcome (Abstract). Schizophrenia Research 1994; 11: 193.
35. Rupniak N, Jenner P, Marsden C. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 88(4): 403-419.
36. Swett CJ. Drug-induced dystonia. American Journal of Psychiatry 1975; 132(5): 532-534.
37. Addonzio G, Alexopoulos G. Drug-induced dystonia in young and elderly patients. American Journal of Psychiatry 1988; 145: 869-871.
38. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 1983; 40: 1113-1117.
39. Casey D. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research 1991; 4: 109-120.
40. Aguilar E, Keshavan M, Martinez-Quiles M, et al. Predictors of acute dystonia in first-episode psychotic patients. American Journal of Psychiatry 1994; 151(12): 1819-1821.
41. Boyer W, Bakalar N, Lake C. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. Journal of Clinical Psychopharmacology 1987; 7: 164-166.
42. Chakos M, Mayerhoff D, Loebel A, et al. Incidence and correlate of acute extrapyramidal symptoms in first-episode of schizophrenia. Psychopharmacology Bulletin 1992; 28: 81-86.
43. Barnes T. Clinical assessment of the extrapyramidal side-effects of antipsychotic drugs. Journal of Psychopharmacology 1992; 6: 214-221.
44. Schröder J, Niethammer R, Geider FJ, et al. Neurological soft signs in schizophrenia. Schizophrenia Research 1992; 6: 25-30.
45. Schröder J, Stockert A, Tittel A, et al. Memory deficits in schizophrenia. Schizophrenia Research 1996; 21: 19-26.
46. Jahn TH, Schroder J, Hubmann W, et al. Clinical and neuropsychological correlates of subtle motor signs in schizophrenia. Submitted for publication.
47. Schröder J, Wenz F, Schad LR et al. Sensorimotor cortex and supplementary motor area changes in schizophrenia. British Journal of Psychiatry 1995; 167: 197-201.
48. Flaum M, Andreasen N. The reliability of distinguishing primary versus secondary negative symptoms. Comprehensive Psychiatry 1995; 36(6): 421-427.
49. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970; 212(Suppl):11-19.
50. Gerlach J, Peacock L. Motor and mental side effects of Clozapine. J Clin Psychiatry 1994; 55(9): 107-109.
51. Rifkin A, Quitkin F, Klein DF. Akinesia. Archives of General Psychiatry 1975; 32: 672-674.
52. Bermanzohn PC, Siris SG. Akinesia: A syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Comprehensive Psychiatry 1992; 33(4): 221-232.
53. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatrica Scandinavica 1994; 380(Suppl): 8-13.
54. Hollister L. Medical progress: complications from the use of tranquilizing drugs. New England Journal of Medicine 1957; 257: 170-177.
55. Van Putten T, May P, Marder S, et al. Subjective response to antipsychotic drugs. Archives of General Psychiatry 1980; 38: 187-190.
56. Sachdev P. Akathisia and restless legs. Cambridge: Cambridge University Press; 1995.
57. Van Putten T, May P, Marder S. Respose to antipsychotic medication: the doctor’s and the consumer’s view. American Journal of Psychiatry 1984; 141(1): 16-19.
58. Weiden P, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In: Shriqui C, Nasrallah H, editors. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press Inc.; 1995: 411-434.
59. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry 1974; 31: 67-72.
60. Levinson D, Simpson G, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry 1990; 47: 761-768.
61. Shriqui C. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Canadian Journal of Psychiatry 1995; 40(Suppl 2): 38-48.
62. Goldstein J. Preclinical tests that predict clozapine-like atypical antipsychotic actions. In: Brunello N, Racagni G, Langer S, Mendlewicz J, editors. Critical Issues in the Treatment of Schizophrenia. Basel: Karger; 1995: 95-101.
63. Goldstein J. Preclinical tests that further distinguish the pharmacological properties of a clozapine-like atypical antipsychotic. In: Beninger R, Palomo T, Archer T, editors. Dopamine Disease States. Madrid: Fundacion Cebebro y Mente; 1996:
299-306.
64. Costall B, Naylor R. Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung 1973; 23: 674-683.
65. Chiodi L, Bunney B. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Journal of Neuroscience 1983; 3(8): 1607-1619.
66. White F, Wang R. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 221: 1054-1057.
67. Goldstein J, Litwin L, Sutton E, Malick J. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 293-298.
68. Casey D. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacology Bulletin 1991; 27(1): 47-50.
69. Goldstein J, Snyder D. Effects of ‘Seroquel’ and other atypical antipsychotics in primate models of EPS. Biological Psychiatry 1995; 37: 646.
70. Carey G, Bergman J. Discriminative stimulus effects of proposed atypical neuroleptics in clozapine-trained squirrel monkeys. Behavioural Pharmacology 1994; 5: 114.
71. Robertson G, Matsumura H, Fibiger H. Induction patterns of Fos-like Immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Journal of  Pharmacology and Experimental Therapeutics 1994; 271(2): 1058-1066.
72. Vahid-Ansari F, Nakabeppu Y, Robertson G. Contrasting effects of chronic clozapine, ‘Seroquel’ (ICI 204,636) and haloperidol administration on delta FosB-like immunoreactivity in the rodent forebrain. European Journal of Neuroscience 1996; 8(5): 927-936.
73. Ellenbroek B, Peeters B, Honig W, et al. The paw test: a behavioural paradigm for differentiating differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 1987; 93: 343-348.

‘Seroquel’ is a trademark of the AstraZeneca group of companies.

[back] [contents] [forward]